Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.
Jan Baptist Vermorken
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Frederic Peyrade
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
Juergen Krauss
No relevant relationships to disclose
Ricard Mesia
Consultant or Advisory Role - Merck
Research Funding - Merck
Eva Remenar
No relevant relationships to disclose
Thomas C. Gauler
Consultant or Advisory Role - Merck
Honoraria - Merck Serono
Ulrich Keilholz
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Jean-Pierre Delord
No relevant relationships to disclose
Philippe Schafhausen
Honoraria - Merck Serono
Jozsef Erfán
No relevant relationships to disclose
Tim H. Brummendorf
Honoraria - Merck KGaA
Lara Iglesias
No relevant relationships to disclose
Ullrich Bethe
Employment or Leadership Position - Merck KGaA
Guillaume de La Bourdonnaye
Employment or Leadership Position - Merck Serono
Paul M. Clement
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono